The Acid Suppression That Refuses to Hold
A single patient whose acid suppression has quietly stopped holding, years into a genetic disease that keeps producing more of the hormone driving it. The disagreement is about whether this is a dosing problem that can still be pushed further, or a disease problem that needs a different drug entirely.
M.F., a 37-year-old high school football coach, was diagnosed with MEN1 four years ago after a workup for recurrent kidney stones turned up hyperparathyroidism, and gastrinoma-driven Zollinger-Ellison syndrome was confirmed the following year when his fasting gastrin came back markedly elevated during evaluation of persistent, multiple duodenal ulcers that kept recurring despite standard-dose acid suppression. He's managed reasonably on high-dose omeprazole since then, tracking his own symptom diary the way he tracks his team's practice schedule — methodically, without complaint — but over the past six weeks his epigastric pain and diarrhea have crept back despite dose increases that have already pushed him toward the upper range typically used even in ZES.
Gastrinoma-driven acid hypersecretion is fundamentally a dose problem before it's anything else — tumor-secreted gastrin drives parietal cell mass and acid output far beyond what standard-dose PPI therapy is calibrated for, which is why ZES patients routinely need two to four times the dose used for ordinary GERD, sometimes higher, titrated directly against measured basal acid output rather than a fixed target. The real question his recent symptom return raises is whether he's simply outgrown his current PPI dose, which can still be pushed further, or whether tumor progression — a live, separately-tracked concern in MEN1-associated gastrinoma given its tendency toward multifocal, sometimes malignant disease — is now driving gastrin output past what acid suppression alone was ever designed to fully counter.
Octreotide, a somatostatin analog, works through an entirely different mechanism: rather than blocking acid production downstream, it suppresses gastrin secretion at the tumor itself. Ruszniewski and colleagues' long-term follow-up of ZES patients on octreotide found sustained reductions in basal and peak acid output over four to five years, with a proposed antitrophic effect on parietal cell mass — real evidence for controlling refractory symptoms, though drawn from a handful of patients, not a population large enough to settle the antitumor question his own team is actually debating. It's also a subcutaneous or depot-injection therapy with its own real burden, not a straightforward dose increase of a pill he already takes twice a day. His most recent fasting gastrin, drawn specifically off PPI interference this visit to get a cleaner read, came back meaningfully higher than the level recorded at his original diagnosis three years ago — the single number both physicians keep returning to as they weigh whether his current picture reflects a dosing gap or a genuinely more active tumor.
Deciding whether this is a dose problem or a disease problem
PPI dosing in Zollinger-Ellison syndrome isn't calibrated the way it is for ordinary GERD — it's titrated directly against measured basal acid output, and patients routinely end up on doses several times what we'd ever use otherwise. His current dose is high, but I don't think we've established it's actually his ceiling.
Before adding a second drug class, I'd want basal acid output measured directly on his current regimen, and push the PPI dose further if that measurement shows room to. Adding octreotide now, before we know that, risks treating a dosing gap as if it were disease progression.
I take the titration point seriously — you're right that we haven't formally measured where his ceiling actually sits.
But he's already at 80 milligrams twice daily, well above what even most ZES patients need, and his symptoms are recurring after a period of real stability. That trajectory change is itself clinically meaningful, and MEN1-associated gastrinomas have a real tendency toward multifocal and sometimes malignant progression that a pure dose-titration frame doesn't account for.
The trajectory change is real and I'm not dismissing it. What I'd flag is what adding octreotide today does to our ability to answer the question you're raising. Basal acid output is the measurement that tells us whether he has genuinely outrun his PPI dose, and it can't be interpreted once a somatostatin analog is suppressing gastrin upstream of it. Nor can his gastrin. If he improves on the combination we will not know which of the two drugs did it, and if his imaging comes back stable we'll have committed him to injections on a symptom flare we never characterized. I'd measure first and add second — not because I think you're wrong about the tumor, but because starting both at once is what makes the tumor question unanswerable.
I'd add octreotide now rather than wait on a longer acid-output titration process — it works at the tumor's own gastrin secretion rather than downstream, and it carries a real, MEN1-relevant antitumor rationale that a further PPI increase simply doesn't offer, regardless of how this particular symptom flare turns out to be explained.
Octreotide added to his current high-dose PPI regimen rather than substituted for it, with basal acid output measurement and repeat imaging both ordered to clarify whether dosing headroom or tumor progression is the actual driver of his symptom return.
Not agreed: whether the octreotide addition should be reconsidered if acid-output measurement later shows real room for further PPI escalation — the Clinical Pharmacologist's titration argument wasn't overruled, only outpaced by a symptom trajectory the Endocrinologist judged too significant to wait on.